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Introduction: DNA methylation is an epigenetic mechanism regulating gene expression that has been insufficiently
studied in the blood of rheumatoid arthritis (RA) patients, as only T cells and total peripheral blood mononuclear
cells (PBMCs) from patients with established RA have been studied and with conflicting results.
Method: Five major blood cell subpopulations: T, B and NK cells, monocytes, and polymorphonuclear leukocytes,
were isolated from 19 early RA patients and 17 healthy controls. Patient samples were taken before and 1 month
after the start of treatment with methotrexate (MTX). Analysis included DNA methylation with high-performance
liquid chromatography-electrospray ionization-tandem mass spectrometry-selected reaction monitoring
(HPLC-ESI-MS/MS-SRM) and expression levels of seven methylation-specific enzymes by quantitative polymerase
chain reaction (qPCR).
Results: Disease-modifying anti-rheumatic drug (DMARD)-naïve early RA patients showed global DNA
hypomethylation in T cells and monocytes, together with a lower expression of DNA methyltrasnferase 1 (DNMT1), the
maintenance DNA methyltransferase, which was also decreased in B cells. Furthermore, significantly increased
expression of ten-eleven translocation1 (TET1), TET2 and TET3, enzymes involved in demethylation, was found in
monocytes and of TET2 in T cells. There was also modest decreased expression of DNMT3A in B cells and of growth
arrest and DNA-damage-inducible protein 45A (GADD45A) in T and B cells. Treatment with MTX reverted
hypomethylation in T cells and monocytes, which were no longer different from controls, and increased global
methylation in B cells. In addition, DNMT1 and DNMT3A showed a trend to reversion of their decreased expression.
Conclusions: Our results confirm global DNA hypomethylation in patients with RA with specificity for some blood cell
subpopulations and their reversal with methotrexate treatment. These changes are accompanied by parallel changes in
the levels of enzymes involved in methylation, suggesting the possibility of regulation at this level.Introduction
Epigenetics has become an area of interest for the study of
rheumatoid arthritis (RA) [1]. It refers to stable but revers-
ible changes in gene expression that are heritable through
cell divisions but do not involve DNA variants. They
maintain the cellular phenotypes acquired during develop-
ment and differentiation, and reflect physiological changes
and environmental stress. This sort of cellular memory is* Correspondence: agmartinezp@ser.es
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in increased fitness, but when aberrant they could pro-
mote or perpetuate a disease status. Epigenetic mecha-
nisms include DNA methylation, histone modifications,
microRNA, other non-coding RNA and nucleosome posi-
tioning. Current interest is based on findings indicating
that epigenetic changes can become biomarkers to differ-
entiate patients from healthy controls and to separate
patient subgroups on prognosis, or on response to treat-
ment, as well as to serve as new targets for treatment [2].
In addition, changes in DNA methylation of blood cells
have been characterized as mediators of genetic risk in RA
and are of interest to understand disease pathogenesis [3].rticle is distributed under the terms of the Creative Commons Attribution 4.0
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characterized epigenetic change [4]. It happens mainly as
5-methylycytosine (5mC) at C–phosphate–G dinucleo-
tides (CpG) by the enzymatic transfer of a methyl group
from S-adenosyl-L-methionine (SAM). In the bulk gen-
ome CpG are rare and highly methylated, but in clusters
of CpG dinucleotides called CpG islands they are usually
non-methylated. When CpG islands at gene promoters
are methylated they are associated with long-term silen-
cing of gene expression. In contrast, variable and tissue-
specific methylation takes place with preference outside
CpG islands [4]. Maintenance of the methylated status
through mitosis requires a specific DNA methyltransfer-
ase (DNMT), DNMT1, which recognizes hemimethylated
DNA sequences and methylates the new DNA strand.
Two other enzymes of the same family, DNMT3A and
DNMT3B, have been characterized as required for de
novo methylation during development or in response to
environmental stimuli or other stress. Active demethyla-
tion depends on the action of the ten-eleven translocation
(TET) (TET1, 2 and 3) enzymes [5]. These enzymes pro-
mote DNA demethylation by converting 5mC to 5-
hydroxymethylcytosine (5hmC), which they further
oxidize into 5-formylcytosine and 5-carboxylcytosine. The
growth arrest and DNA-damage-inducible protein 45A
(GADD45A) enzyme could also contribute to demethyla-
tion [6], especially in autoimmune diseases [7, 8].
Global DNA hypomethylation has been found in sev-
eral inflammatory and autoimmune diseases where it en-
tails aberrant expression of genes and ribosomal RNAs
probably implicated in their pathology [9, 10]. Other
changes associated with DNA hypomethylation as genome
instability and mutations, or use of cryptic promoters have
not been described in the autoimmune diseases. In RA,
DNA hypomethylation has been thoroughly demonstrated
in fibroblast-like synovial (FLS) cells [11–14]. Hypomethy-
lation at specific CpG sites in FLS is associated with over-
expression of genes that are keys for the disease process.
The consequences of DNA hypomethylation in FLS have
been highlighted by the activated phenotype that normal
FLS acquire after drug (5-azacytidine)-induced demethyla-
tion [11]. However, many aspects of DNA methylation in
RA remain incompletely explored or are controversial.
For example, there are conflicting reports regarding
changes in DNA methylation of blood cells [15, 16], or
the expression of methyltransferase enzymes [11, 13, 16].
Also, we do not know the methylation status of other im-
portant players in RA beyond FLS and blood T cells, the
only cell populations studied to date [11–14, 17]. In
addition, all the previous studies have analyzed samples
from established RA patients and could reflect effects of
treatment or of disease evolution. In this respect, there is
a report indicating that methotrexate (MTX) reverts DNA
hypomethylation in inflammatory arthritis [18], in spite ofMTX inhibition of SAM synthesis [19, 20]. Finally, some
previous studies have evaluated global DNA methylation
with techniques that are insensitive and unable to distin-
guish 5mC from 5hmC, which has different functional im-
plications. These design and technical issues could have
contributed to some of the previous discordant results.
Therefore, we aimed to address some of these questions
with disease-modifying anti-rheumatic drug (DMARD)-
naïve early RA patients, before and after receiving MTX
and using sensitive and accurate technology [21, 22].
Methods
Patients and controls
New consecutive patients arriving to the Rheumatology
Unit and fulfilling the 2010 American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) classification criteria for RA were included
from April 2011 to February 2012 [23]. All had clinical
symptoms of less than 2 years of evolution compatible
with their classification as early RA. Clinical data and
blood samples were taken before and 1 month after start-
ing treatment with MTX. Clinical follow-up was done
with complete independence from this study. Gender and
age-matched healthy controls were recruited at the same
time. All patients and controls were of Caucasian Spanish
ancestry. The Ethics Committee for Clinical Research of
Galicia approved this study, and written informed consent
was obtained from all participants.
Blood cell subpopulations
Double gradient separation by centrifugation was used
to isolate granulocytes and mononuclear cells with
Histopaque®-1077 and Histopaque®-1119 (Sigma-Aldrich,
St Louis, MO, USA) from 20 mL of EDTA anti-
coagulated blood as described [24]. Mononuclear cells
forming the buffy coat over the 1077 layer were fraction-
ated by immune-magnetic positive selection in four sub-
populations CD56+ (natural killer (NK) cells), CD14+
(monocytes), CD19+ (B lymphocytes) and CD3+ (T lym-
phocytes). The MACS® system (Miltenyi Biotek Bergisch
Gladbach, Germany) was used for NK cells and BD
IMag™ cell separation system (BD Biosciences, San Jose,
CA, USA) for the other subpopulations. Purity of the
isolated cells was controlled by fluorescence-activated
cell sorting analysis on a FACScan™ cytometer with Cell-
Quest Pro Software (BD Biosciences) as double-stained
cells with anti-CD45 PE and subpopulation-specific
antibodies labeled with FITC (anti-CD14, CD19, CD3
for the populations purified with these antibodies and
anti-CD15 for granulocytes) and as CD56+ and CD3−
cells for the NK cells. All antibodies were from BD
Biosciences. Purity of isolated cell subpopulations
ranged from 90 to 99 %. Purified cells were processed
with the illustra™ triplePrep Kit (GE Healthcare. Little
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tions to obtain genomic DNA and total RNA.
Global DNA methylation
5mC relative levels were quantified following enzymatic
hydrolysis of genomic DNA as described [21]. Three
standards were included in each analysis. They were
identical DNA sequences except for the inclusion of 100
% unmodified cytosines, 100 % 5mC or 100 % 5hmC, re-
spectively (Zymo Research, Irvine, CA, USA). Samples
and standards, 0.1–1 μg, were hydrolyzed to their com-
ponent nucleosides before analysis by incubation with
DNA Degradase Plus (Zymo Research) for 2 h at 37 °C.
Separation and quantification of the nucleosides was
done by high-performance liquid chromatography-
electrospray ionization-tandem mass spectrometry-
selected reaction monitoring (HPLC-ESI-MS/MS-SRM)
in the API 4000 LC/MS/MS System (AB Sciex, Framing-
ham, MA, USA) including a ZORBAX Eclipse XDB-C18
column (Agilent Technologies, Santa Clara, CA, USA)
and a triple quadrupole mass spectrometer. This system
allows the accurate and sensitive differentiation of 5mC
from the four deoxyribonucleosides, the four ribonucleo-
sides and 5hmC [21]. Quantification was expressed as
the ratio of 5mC to total cytosine (5mC/5mC+C).
DNA methyltranferase expression analysis
Total RNA from each cell subpopulation was immediately
reverse-transcribed with avian myeloblastosis virus reverse
transcriptase (Promega, Madison, WI, USA) and random
primers. Gene expression of DNMT1, DNMT3A,
DNMT3B, TET1, TET2, TET3 and GADD45A was quanti-
fied with quantitative polymerase chain reaction (qPCR).
Primers were designed with the primer Express 3.0 soft-
ware (Applied Biosystems, Foster City, CA, USA) (Table
S1 in Additional file 1). Five housekeeping genes were ini-
tially tested (RPL13A, GAPDH, B2M, 18S and TBP) as re-
ported [25]. Those showing stable expression (TBP and
18S for all cell subpopulations except granulocytes, where
only TBP showed stable levels) in qBase [26] were used as
reference. Quantifications were performed in triplicate 10
μl reactions containing 1 μl cDNA, 5 μl RT2 SYBR Green
qPCR Mastermix (Qiagen, Venlo, The Netherlands), and
250 nM of each primer in a Rotor-Gene™ 6000 (Corbett
Life Science, Venlo, The Netherlands) thermocycler with
initial activation at 95 °C for 10 minutes, followed by a
two-step program of 95 °C for 15 seconds and 60 °C for 60
seconds for 45 cycles (gain = 8). Standards were included
in each run for inter-run calibration. Specificity of the PCR
reactions was confirmed by melting curve analysis of the
products as well as by size verification by DNA electro-
phoresis. Transformed expression data were analyzed with
qBase after adjusting for amplification efficiency of each
transcript [26].Statistical analysis
Data analysis was performed with Statistica 7.0 (StatSoft,
Tulsa, OK, USA). Non-normality of the variables was
corrected with logarithm or power transformations. Dif-
ferences between patients and controls were evaluated
using main effects analysis of variance with covariates
(ANCOVA). Covariates were sex and age. Within-
patient comparisons, before and after MTX treatment,
were done with paired-samples t tests.
Results
Characteristics of patients, controls and the isolated
blood cell subpopulations
A total of 19 consecutive patients with RA starting
MTX treatment were recruited (Table 1). The fraction of
men (73.7 %) was higher than the typical of patients with
RA. Symptoms had started a median of 6.0 months be-
fore MTX treatment with only three patients surpassing
the year since the first symptoms and none with more
than 20 months of evolution. These patients had not re-
ceived DMARDs before starting MTX. All had already
been treated with low-dose methylprednisolone (4–10
mg/day) for a median of 23 days before starting MTX
(interquartile range (IQR) 12–33.5 days). Activity of RA
was moderate in most patients with mean disease activ-
ity score in 28 joints (DAS28) of 4.6. Only two of the pa-
tients showed erosions on radiographic exploration in
spite of the presence of anti-citrullinated peptide anti-
bodies (ACPA) or rheumatoid factor (RF) positivity in
more than half of them (63.2 % seropositive). The initial
dose of MTX was 10 mg/week except for one patient
who received 15 mg/week. A second sample from each
patient was taken 1 month after starting MTX treatment
to assess the effect on DNA methylation and expression
of DNMTs, TETs and GADD45A. All patients were in
MTX monotherapy at that time and without change in
MTX or methylprednisolone doses. Although 1 month
is too early for assessing response to MTX, a decrease of
RA activity was already evident in most patients
(Table 1). Response to MTX was assessed at 6-month
follow-up. At that time, 15 patients remained in mono-
therapy with MTX, 12 of them showed good response
according to the EULAR criteria [27], one showed a
moderate response and two were non-responders. Of
the four patients not remaining on MTX monotherapy
at 6 months, two were on a different DMARD due to in-
efficacy of MTX and two had interrupted MTX due to
adverse effects. A total of 17 healthy controls matched
for age and sex were recruited and studied.
Three subpopulations of blood cells monocytes, B and
T lymphocytes were isolated from the 19 patients and
17 healthy controls. Granulocytes and NK cells were also
isolated in the first eight patients and eight controls but
not pursued further because no differences were
Table 1 Characteristics of the patients with early RA and of the
healthy controls included in the study
RA patients Healthy controls
Number 19 17
Female, (%) 5 (26.3) 6 (35.3)
Age at diagnosis, median (IQR) 61.6 (51–65) 58 (39–64)
Symptoms to MTX, median
months (IQR)
6.0 (2.2–7.3)
RF (%) 11 (57.9)
ACPA (%) 11 (57.9)
Erosive arthritis (%) 2 (10.5)




Metothrexate, median mg/week (IQR) 10 (10–10)
CRP (mg/L), median (IQR)
Baseline 15.3 (3.9–23.2)
1 month 5.2 (1.2–9.4)
ESR, median (IQR)
Baseline 28.0 (6.0–38.0)
1 month 14.0 (6.5–24.0)
DAS28, mean ± SD
Baseline 4.6 ± 1.6
1 month 3.2 ± 1.5
RA rheumatoid arthritis, IQR interquartile range, MTX methotrexate, RF
rheumatoid factor, ACPA anti-citrullinated peptide antibody, CRP C-reactive
protein, ESR erythrocyte sedimentation rate, DAS28 disease activity factor
in 28 joints, SD standard deviation
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tions will not be presented in detail. Purity of the iso-
lated subpopulations ranged from 90 to 99 %.
Differences in global DNA methylation between patients
with RA and controls
Levels of global 5mC were similar to those previously
reported [21, 22]. Comparison of the global 5mC level
between patients and controls was done with the sam-
ples of RA patients before MTX treatment. Main effects
ANCOVA with sex and age as covariates was used for
these comparisons. T lymphocytes showed significant
DNA hypomethylation in early RA patients compared
with healthy subjects (Fig. 1a; mean = 3.89 %, 95 % con-
fidence interval (CI) = 3.80–3.99 vs. 4.15 %, 95 % CI =
3.96–4.38, respectively, P = 0.011). The multivariate ana-
lysis also showed significant DNA hypomethylation in the
monocytes of RA patients (Fig. 1c; mean = 3.96 %, 95 %
CI = 3.87–4.07 vs. 4.13, 95 % CI = 3.98–4.33, respectively,
P = 0.047). Although significant, these differences were
small. No significant differences were detected in any of
the other blood cell subpopulations: B lymphocytes, NKcells and polymorphonuclear (PMN) cells (Fig. 1b and not
shown). No significant correlation between the total meth-
ylprednisolone dose received until blood drawing and
levels of 5mC in any of the five blood subpopulations were
observed in RA patients (not shown). In the same assay,
5hmC was also determined without any significant differ-
ence between patients and healthy controls, showing very
low levels in all cell subpopulations (around 0.02 % of total
cytosine) as is characteristic of most adult tissues [21, 28].
DNMT1, DNMT3A, DNMT3B, TET1, TET2, TET3 and
GADD45A relative expression was determined by qPCR
analysis in each of the blood cell subpopulations. A signifi-
cant decrease in patients with RA was observed for some
enzymes: DNMT1 expression was decreased in T cells
(Fig. 2a; mean = 5.6, 95 % CI = 4.3–7.2 vs. 10.0, 95 %
CI = 7.7–13.1; P = 0.0022), B cells (Fig. 2b; mean = 3.4,
95 % CI = 2.6–4.3 vs. 6.0, 95 % CI = 4.6–7.4; P = 0.00046)
and monocytes (Fig. 2c; mean = 5.6, 95 % CI = 4.5–6.7 vs.
8.4, 95 % CI = 7.4–9.4; P = 0.00020); DNMT3A was de-
creased, although less markedly, in B cells (Fig. 2d;
mean = 27.5, 95 % CI = 17.9–42.2 vs. 46.9, 95 % CI =
32.4–67.9; P = 0.044); no difference was found in the ex-
pression of DNMT3B in any of the blood cell subpopula-
tions (not shown); and GADD45A expression was also
moderately reduced in T cells (Fig. 2e; mean = 12.2, 95 %
CI = 8.7–17.3 vs. 20.0, 95 % CI = 13.9–28.8; P = 0.048)
and in B cells (Fig. 2f; mean = 9.6, 95 % CI = 5.8–45.9 vs.
18.3, 95 % CI = 12.9–25.9; P = 0.021). On the contrary,
the relative expression of TET enzymes was increased in
some cell populations. Monocytes showed the largest in-
creases, with the three TET enzyme genes showing higher
relative levels of expression in RA patients than in con-
trols. TET1 and TET3 showed the most marked difference
between RA patients and controls (TET1, Fig. 3a; mean =
2.9, 95 % CI = 2.1–4.8 vs. 1.9, 95 % CI = 1.6–2.3; P =
0.0044; and TET3, Fig. 3c; mean = 2.0, 95 % CI = 1.7–2.3
vs. 1.35, 95 % CI = 1.15–1.6; P = 0.0014), but also TET2
(Fig. 3b; mean = 2.5, 95 % CI = 1.9–3.2 vs. 1.8, 95 % CI =
1.5–2.2; P = 0.019) was increased in monocytes of the pa-
tients with RA. TET2 was also modestly increased in the
T cells of RA patients in relation with the healthy controls
(Fig. 3d; mean = 3.4, 95 % CI = 2.4–5.2 vs. 2.2, 95 % CI =
1.8–3.0; P = 0.045). No other differences were detected.
Increase of global DNA methylation after MTX treatment
Global DNA methylation was analyzed 1 month after
starting treatment with MTX. Comparison of the percent-
age of 5mC in each of the five blood cell subpopulations
with t tests for dependent variables showed significant in-
creases after treatment in three of them: T cells that
showed the most significant increase in global DNA 5mC
(Fig. 4a; mean = 4.21 %, 95 % CI = 4.03–4.43 after 1
month of treatment; P = 0.0014), B cells (Fig. 4b; 4.09
%, 95 % CI = 3.94–4.28 after treatment vs. 3.94 %, 95 %
Fig. 1 Differences in global DNA methylation between healthy controls (HC) and early rheumatoid arthritis (RA) patients. The percentage of
5-methylcytosine (5mC) over the total content of cytosine in total DNA of a T cells, b B cells, and c monocytes is shown. Each dot represents a
subject. Horizontal bars with an empty square are means. Differences in (a) and (c) were significant, P < 0.05
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that showed a borderline increase (Fig. 4c; 4.09 %; 95 %
CI = 4.00–4.21 after 1 month of treatment; P = 0.045).
However, some patients did not follow this trend to re-
covery (Fig. 4). No differences in 5mC were detected in
NK or PMN cells between baseline and after 1 month
with MTX. No detectable variation in global 5hmC
levels was observed (data not shown).
We have also compared expression of DNMT1,
DNMT3A, DNMT3B, GADD45A, TET1, TET2 and TET3
in the five cell subpopulations after MTX treatment with
their baseline levels. No clear changes were observedFig. 2 Expression of methylation enzymes in blood cells of healthy control
expression of DNMT1 obtained by quantitative polymerase chain reaction (
and of GADD45A in T cells (e) and B cells (f) is shown. Other conventions a
in other cells subpopulation and none of the DNMT3B analyses were signif(Fig. 5). Only DNMT1 showed a trend to increased levels
after treatment in T cells and monocytes that was near
significant (P = 0.06 and 0.07, respectively). A not sig-
nificant trend to an increase of DNMT3A in B cells (P =
0.06) was also observed. No similar trend was found for
any of the other enzymes. On the contrary, the differ-
ences with healthy controls that were present before
treatment were still present after 1 month on MTX ex-
cept for TET2 in T cells that was no longer significantly
different. In particular, the TET enzyme expression in
monocytes showed the same level of difference with
healthy controls than before treatment (TET1 Pbefore =s (HC) and early rheumatoid arthritis (RA) patients. Normalized relative
qPCR) in a T cells, b B cells, and c monocytes, DNMT3A in B cells (d)
re as in Fig. 1. All these comparisons were significant. No comparison
icant
Fig. 3 Differences between healthy controls (HC) and early rheumatoid arthritis (RA) patients in ten-eleven translocation (TET) enzymes expression.
Normalized relative expression of a TET1, b TET2, and c TET3 in monocytes; and of d TET2 in T cells. Conventions are as in Fig. 1. All differences
were significant at P < 0.05
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and TET3 Pbefore = 0.0014, Pafter = 0.0033), as well as the
expression of GADD45A in T and B cells (T cells Pbefore =
0.048, Pafter = 0.049; B cells Pbefore = 0.021, Pafter = 0.041).
Therefore, TET enzyme gene expression in monocytes
and GADD45A in T and B cells were not significantly
modified by this treatment.Fig. 4 Increased global DNA methylation in rheumatoid arthritis (RA) pati
5-methylcytosine (5mC) over the total content of cytosine in total DNA o
joined by dashed lines represents a subject before and after MTX. All chanDiscussion
Our results support the involvement of decreased DNA
methylation in RA and its reversal in response to MTX.
They also widen the spectrum of changes in methylation
and in the enzymes regulating this process in RA, as well
as provide cell-specific results. In particular, this is the
first time that changes in B cells and in monocytes haveents after 1 month on methotrexate (MTX). The percentage of
f a T cells, b B cells, and c monocytes is shown. Each pair of dots
ges were significant with P < 0.05
Fig. 5 Largest changes in expression of methylation enzymes after 1 month on methotrexate (MTX). Normalized relative expression of a DNMT1
in T cells, and b in monocytes, and c DNMT3A in B cells, before and after 1 month on MTX is shown. Figure conventions are as in Fig. 4. The
three changes showed P < 0.1, but none was significant
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enzymes have been studied in the blood of RA patients.
The results support the implication of DNA hypomethy-
lation in RA and highlight the interaction between MTX
and DNA methylation that could contribute to its thera-
peutic efficacy in RA.
A couple of previous studies have analyzed whole
peripheral blood mononuclear cells (PBMCs) with dis-
cordant results [15, 16]. One of these studies found
global DNA hypomethylation in PBMCs with an
enzyme-linked immunosorbent assay (ELISA) kit of
questionable accuracy given the low percentage of
5mC (1.22 % in controls) [16] in comparison with
our results, other results in RA T cells [17], and in
other cells and tissues [21, 22]. The second study did
not find differences in DNA methylation between
PBMCs of RA discordant monozygotic twins at 1505
CpG sites analyzed by bead array [15]. However, these
sites were not randomly distributed and their repre-
sentativeness of global DNA methylation is uncertain,
and could be insensitive to detect the small difference
we have observed. The most specific study to date
has analyzed PBMCs in two subsets, T cells and non-
T cells, with a HPLC method [17]. The T cells
showed global DNA hypomethylation, whereas the
non-T cells did not. These results are in agreement
with our observations.
Meaning of global DNA hypomethylation in auto-
immune diseases has been best studied in systemic lupus
erythematosus (SLE) CD4 T cells. These cells show global
and site-specific hypomethylation that is associated with
increased expression of immune response genes, many of
them in the interferon (INF) signaling pathway, overex-
pression of ribosomal RNA, modifications of imprinting,
and reactivation of endogenous retrovirus [8–10, 29]. All
these changes could contribute to the breakdown of im-
mune tolerance and to chronic inflammation. Support of
this causal role has been provided by the drug-induced
SLE that follows treatment with hydralazine orprocainamide, which decrease DNA methylation, and by
animal studies [8–10]. Although some of the above-
mentioned changes could be SLE-specific, it is likely that
DNA hypomethylation in RA T cells has a similar role. In
this regard, there is already evidence showing that specific
CpG sites at TNFSF5 are similarly hypomethylated in T
cells of SLE and RA [30]. In addition, a recent large study
in RA has found evidence for methylation changes in
PBMCs as possible mediators in genetic susceptibility [3].
As already mentioned, global DNA methylation has
not been previously analyzed in monocytes of RA pa-
tients. In SLE, monocytes share several hypomethylated
sites with CD4 T cells, although they were more numer-
ous and prominently hypomethylated in T cells [29]. In
RA monocytes, the methylation level at a CpG site in
the IL6 promoter that was hypomethylated in RA
PBMCs was inversely correlated with interleukin (IL)-6
lipopolysaccharide (LPS)-induced expression [31]. It can
only be presumed that changes in methylation as this
one could also contribute to the disease process.
DNMT1 was the most markedly and consistently de-
creased DNA methyltransferase in our study. This result
is in contrast with a previous report that found increased
DNMT1 expression in PBMCs of RA patients [16], but it
is in agreement with multiple observations in other
autoimmune diseases [8, 9, 15]. In addition, impaired
DNMT1 function has a causal role in global DNA hypo-
methylation and autoimmunity as demonstrated by drug-
induced SLE [9]. In RA, studies of DNMT1 have been
much more limited and restricted to FLS in culture. They
show comparable levels to the observed in osteoarthritis
(OA) FLS, but DNMT1 expression is markedly downregu-
lated by incubation with small amounts of inflammatory
cytokines [11, 13]. These previous reports suggest possible
mechanisms for the decreased DNMT1 expression and in-
dicate that downregulation of DNMT1 is very likely a
major factor in DNA hypomethylation. However, correl-
ation between DNMT1 levels and DNA hypomethylation
was not present in B cells in our study. The lack of
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cause they were the only cell type showing decreased ex-
pression of DNMT1 and DNMT3A. No reduction of
DNMT3A levels has been previously described in RA FLS
or in SLE T cells [13, 32–34], which are the two cell types
that have been studied. In turn, no differences in
DNMT3B have been described in agreement with our
negative results regarding this enzyme [13, 32–34].
In addition to the changes in the enzymes that methy-
late DNA, our study is the first addressing the DNA
demethylases in an autoimmune disease. Expression of
the genes for the three TET enzymes were increased in
the monocytes of RA patients, and TET2 was also in-
creased in T cells. These results could contribute to-
gether with the decrease in DNMT1 to the global
hypomethylation observed in the patients. Of possible
relevance for RA is that the TET3 locus has been associ-
ated with SLE susceptibility in Asians [35], and that
TET1 regulates transcription and processing of IL1β and
other pro-inflammatory genes in experiments with cell
lines [36]. Previously, GADD45A was the main known
active DNA demethylase [6], however this role seems to
correspond to the TET enzymes [5]. However, interest in
GADD45A has remained in the autoimmune diseases
because it is overexpressed in CD4 T cells of SLE
patients, correlating with global and site-specific DNA
hypomethylation in these cells [7, 8]. In contrast,
GADD45A expression was diminished in our analysis of
RA patients, both in T and B cells. The observed decrease
is not congruent with global DNA hypomethylation in
T cells given its proposed demethylating function, but
GADD45A has other functions and one of them could
have a role here: its role as inhibitor of T cell receptor
(TCR) signaling [37].
Several of the differences we observed in RA patients
were reverted after 1 month of MTX treatment. First, glo-
bal DNA hypomethylation in T cells, B cells and mono-
cytes was reverted in most patients. These results are
reminiscent of a smaller study including patients with in-
flammatory arthritis (RA and psoriatic arthritis (PsA)) on
long-term treatment with MTX [18]. This outcome is con-
trary to the expected given the MTX suppression of SAM
[38], which is the major source of methyl groups for DNA
methylation. However, control of inflammation by MTX
could lead to reduced cell proliferation, which is a source
of SAM consumption through increased recycling of poly-
amines [39], and to reversal of DNMT1 and DNMT3A
expression given their sensitivity to pro-inflammatory
cytokines [11, 13]. The two mechanisms could contribute
to the recovery of DNA methylation.
Conclusions
Our results support the implication of DNA methylation
in RA and in its response to MTX treatment. They alsowiden the spectrum of changes and the types of cells
that are affected by them: global DNA hypomethylation
in T cells and monocytes associated with a lower expres-
sion of DNMT1 and increased expression of the three
TET enzymes in monocytes and TET2 in T cells, to-
gether with decreased DNMT1 and DNMT3A expression
in B cells. Several of these changes were reverted after
MTX treatment, most remarkably the DNA global hypo-
methylation. The differences and changes found here in
peripheral blood could reflect important mechanisms
both in disease evolution and in its control by MTX and
suggest multiple new areas of future research.
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